title: A phase I study of elesclomol sodium in patients with acute myeloid leukemia.
authors.forename: David
authors.initials: D
authors.lastname: Hedley
authors.forename: Aisha
authors.initials: A
authors.lastname: Shamas-Din
authors.forename: Sue
authors.initials: S
authors.lastname: Chow
authors.forename: Deborah
authors.initials: D
authors.lastname: Sanfelice
authors.forename: Andre C
authors.initials: AC
authors.lastname: Schuh
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Brandwein
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Seftel
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Karen W L
authors.initials: KW
authors.lastname: Yee
authors.forename: Aaron D
authors.initials: AD
authors.lastname: Schimmer
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006834:Hydrazines; C512195:elesclomol